focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
In my view there’s no Smoke with out fire
Just bought another £10k here in expectation of good news!
Southampton, UK - 21 July 2020: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company which originated from research at the University of Southampton, issues clarification with respect to yesterday's announcement
§ The trial of SNG001 in hospitalised COVID-19 patients is a Phase II trial (as clearly stated in the announcements of 18 and 25 March). A Phase II trial is designed to test the efficacy of a drug and takes place before the drug is approved or able to be marketed.
§ The protocol was approved by both MHRA and HRA (as detailed in announcement of 18 March) and further details can be found in respect of the full study on the Company's website https://www.synairgen.com/investors/presentations
§ As per the announcement of yesterday, the Company will be working with the regulators and other key groups to progress this potential COVID-19 treatment as rapidly as possible. As with any drug undergoing clinical trials, Synairgen will require regulatory approval before SNG001 can be marketed on a commercial basis.
The Company will provide additional updates in due course and will continue with further analysis of the data from the trial.
Synairgen and Vectura Group are old College Budies
The two companies grew Up Together
News will come out Sooner or Later
Vectura mesh nebulisers with the Synairgen Vaccine
Makes a Winning product
Hello David. Thanks for your message. As a leading inhalation CDMO, as you would expect, we hold exploratory talks with many potential customers related to, amongst others, COVID-19 disease as well as other inhaled treatments. Signing new business of a material nature is always communicated by press release on the Regulatory News Service (RNS). We promote our RNS updates on http://www.vectura.com and in our social media channels. Thanks again for your interest.
Good news ,although expected today,confirming an additional $6.25mill in milestone payments & low single digit royalties from Europe & Japan,more buyers than sellers,continued buy back....& yet our SP continues to be weak.More positive news soon + a positive half year trading update will hopefully see our SP head North over the coming weeks
yes there are alot of things coming to light
130 pence stiil on the cards
Vecturaking, anything from the webinar?
in my view we have 130 Pence for the short term here on the cards
with imminent news Breaking on various points
vectura maintaining the second quarter forecasts
great portfolio of products and favourable news stream
i believe that they are best suited to Announce Major JV Deals
i note that this may effect there buyback program
but being transparent is of Great importance
good luck all
Webcast today should result in a re reate if we are lucky and our inhalers breathe new life into the company.
Vectura is the leader in inhaled products
Due to the covid Situation this has Opened up
Numerous opportunities with major players to be announced shortly in my view
Make no mistake we are going a lot Higher due to a ReRating
Enjoy the lovely weather
https://www.reuters.com/article/us-health-coronavirus-gilead-sciences-idUSKBN23T1Y9
Register for our LIVE webcast with @VecturaGroup "Dry Powder Inhalers: Key Considerations for Combination Product Development" on Wednesday June 24, 2020 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST
ow.ly/ChwU50AcREx
In my view Vectura is the leaders in inhalers and are partnering with GILEAD Sciences to administer the drugs via the inhalers
That’s what I can see behind the scenes
Thanks, interesting. I can see the overlap.
It looks like it was the buyback putting the floor in on Friday. Once it dropped below 103.3 they could purchase, timing of the buybacks matched the drops below this level.
Cap today is 105.3 .
NFX takeover ?
Massive buy shows why our SP was firm into the close -a very positive sign
Todays cap is about 103 (using the prices of this site), this may have put the floor under the role back of the price.
It will be interesting to see, the timing and the price if there has been any buybacks today.
They were capped at 100p yesterday by the buyback rules , so only 75k purchased up until lunch time.
The main part of yesterdays rise was after this - so not due to the buyback.
Warren, I believe you are correct - I thought this would get a lift from increased sales as users of their products ensured they had 'spares' as insurance against disruption during the pandemic. I also expected more being prescribed. An outside chance is collaboration on an inhaled product for covid. Any of the above may be announced -we shall see.
It’s rising because news is coming and someone is gathering shares .
It is currently third on the ftse 250 reserve list, but is circa 140m MCap behind the other two,(CMC/BH Macro) so it looks to be either buying on fundamentals and/or the share buy back pushing it up rather than arbitraging for an index change.
The buyback really seems to be helping push the price up this time. I was expecting the usual retrace once we touched 99p so pleasantly surprised when it motored through.
Tomorrow should be interesting as, if my calculations are correct, they will only be able to buy when/if the price is under 103.3 .
Stormed through 100p today after a few days of building on gains -so let’s hope we can hold the higher ground & build in it based on positive newsflow
A CORONAVIRUS vaccine developed by scientists at the University of Oxford administered using an inhaler, could be ready by as early as August.
in my view i think Vectura are the leaders in Inhalers will benefit from this in a mega way
https://www.irishpost.com/news/oxford-university-scientists-80-vaccine-will-work-and-it-could-be-ready-in-a-few-weeks-186402